Article

The Globe and MailThe Globe and Mail on 2017-09-28 03:47

Canadian regulator orders price cut of expensive U.S. drug Soliris

In a landmark decision released Wednesday, a panel of the Patented Medicine Prices Review Board (PMPRB) ruled that Connecticut-based Alexion ...

Related news